Top 5 Biotechnology VC (Venture Capital) Funds in Iceland in October 2023

Portfolio highlights

• PaxFlow — We empower tour operators to streamline operations PaxFlow helps streamline tour operations with resource management, data based workflows, customer communication and self service tools. Discover Streamlined Tour Management PaxFlow integrates with leading booking system providers and integrates booking data with operational features like resource management, shift scheduling, departure management and customer self service portal to...
• Vitar Games — A WW1 Strategy driven Management Game
• Standby Deposits — Standby Deposits is a rental security deposit replacement based on credit.

Portfolio highlights

• EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases

Portfolio highlights

• AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
• XNK Therapeutics — XNK Therapeutics, founded in 2012, is one of the pioneering companies within the landscape of cell therapy.
• Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.

Portfolio highlights

• Polka Pop — Polka Pop is India's first brand to serve naturally flavored sparkling water with zero calories and no added sugar. Supporting a sustainable lifestyle choice, this healthy drink is available in four flavors, i.e. lemon-lime, orange, peach, and cranberry. The fizz makes this the best mix for cocktails and mocktails.
• EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases

Portfolio highlights

• Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.